Results 11 to 20 of about 66,503 (250)
Development of New Drugs for Autoimmune Hemolytic Anemia
Pharmaceutics, 2022 Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging.
Zhengrui Xiao, Irina Murakhovskaya
doaj +2 more sources
The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
Frontiers in Immunology, 2023 Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in most cases of warm-antibody AIHA, cold agglutinin disease is treated by targeting the ...
S. Berentsen, B. Fattizzo, W. Barcellini
semanticscholar +1 more source
Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps
Frontiers in Immunology, 2023 Autoimmune hemolytic anemia (AIHA) is an acquired hemolytic disorder, mediated by auto-antibodies, and has a variable clinical course ranging from fully compensated low grade hemolysis to severe life-threatening cases.
Femke V. M. Mulder +7 more
semanticscholar +1 more source
Autoimmune hemolytic anemia: causes and consequences
Expert Review of Clinical Immunology, 2022 Introduction Autoimmune hemolytic anemia (AIHA) is classified according to the direct antiglobulin test (DAT) and thermal characteristics of the autoantibody into warm and cold forms, and in primary versus secondary depending on the presence of ...
B. Fattizzo, W. Barcellini
semanticscholar +1 more source
How I treat warm autoimmune hemolytic anemia.
Blood, 2021 Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation.
W. Barcellini, B. Fattizzo
semanticscholar +1 more source
Autoimmune Hemolytic Anemia After mRNA COVID Vaccine
Journal of Investigative Medicine High Impact Case Reports, 2022 Discussion of the hematologic complications of vaccination for severe acute respiratory syndrome coronavirus-2 (COVID-19) has primarily focused on the development of vaccine-associated immune thrombosis with thrombocytopenia (VITT).
Z. Fatima +3 more
semanticscholar +1 more source
Journal of Thrombosis and Haemostasis, 2022 Thrombosis may complicate autoimmune hemolytic anemia (AIHA), but its predictors are still lacking, and no clear‐cut indications for anticoagulant prophylaxis are available.
B. Fattizzo +5 more
semanticscholar +1 more source
Warm autoimmune hemolytic anemia and the best treatment strategies.
Hematology. American Society of Hematology. Education Program, 2022 Warm autoimmune hemolytic anemia (wAIHA) is characterized by evidence of red blood cell (RBC) hemolysis and a direct antiglobulin test positive for IgG and sometimes complement. While varying with the extent of the compensatory increase in RBC production,
D. Kuter
semanticscholar +1 more source
European Journal of Haematology, 2022 Autoimmune hemolytic anemia (AIHA) is considered a chronic disease, with an overall good prognosis. However, recent reports indicate pre‐mature mortality. Causes of death have not been evaluated previously.
D. Hansen, S. Möller, H. Frederiksen
semanticscholar +1 more source
Autoimmune Hemolytic Anemia in the Pediatric Setting
Journal of Clinical Medicine, 2021 Autoimmune hemolytic anemia (AIHA) is a rare disease in children, presenting with variable severity. Most commonly, warm-reactive IgG antibodies bind erythrocytes at 37 °C and induce opsonization and phagocytosis mainly by the splenic macrophages ...
Aikaterini Voulgaridou, T. Kalfa
semanticscholar +1 more source